CD274 and prostate cancer: Therefore, clinical trials designed for combining anti-PD-1/PD-L1 agents with other anticancer treatments, including inhibitors of different immune checkpoint pathways or other systemic anticancer treatments, mostly failed in prostate cancer at the current stage (Table 1).